Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
Qualigen Therapeutics (NASDAQ: QLGN) announced a strategic partnership with BitGo on October 23, 2025 to execute its first multi-asset C10 treasury allocation.
The company committed a $30 million market-cap-weighted basket of the world’s top 10 crypto assets (excluding stablecoins). BitGo will provide OTC execution, access to deep liquidity, and regulated cold custody with compliance protocols to safeguard Qualigen’s treasury assets.
The move formalizes Qualigen’s shift toward a diversified digital-asset treasury strategy and leverages BitGo’s institutional infrastructure to streamline treasury operations.
Qualigen Therapeutics (NASDAQ: QLGN) ha annunciato una partnership strategica con BitGo il 23 ottobre 2025 per eseguire la sua prima allocazione di tesoreria multi-asset C10.
L'azienda ha impegnato un paniere ponderato per capitalizzazione di mercato di 30 milioni di dollari tra i primi 10 asset crypto mondiali (escluse le stablecoin). BitGo fornirà esecuzione OTC, accesso a profonda liquidità e custodia fredda regolamentata con protocolli di conformità per salvaguardare le attività della tesoreria di Qualigen.
La mossa formalizza lo spostamento di Qualigen verso una strategia di tesoreria in asset digitali diversificata e sfrutta l'infrastruttura istituzionale di BitGo per snellire le operazioni di tesoreria.
Qualigen Therapeutics (NASDAQ: QLGN) anunció una asociación estratégica con BitGo el 23 de octubre de 2025 para ejecutar su primera asignación de tesorería multi-activo C10.
La empresa comprometió una canasta ponderada por capitalización de mercado de 30 millones de dólares de los 10 principales activos cripto del mundo (excluyendo stablecoins). BitGo proporcionará ejecución OTC, acceso a una profunda liquidez y custodia fría regulada con protocolos de cumplimiento para salvaguardar los activos de tesorería de Qualigen.
El movimiento formaliza el cambio de Qualigen hacia una estrategia de tesorería de activos digitales diversificada y aprovecha la infraestructura institucional de BitGo para optimizar las operaciones de tesorería.
Qualigen Therapeutics (나스닥: QLGN)은 2025년 10월 23일 BitGo와의 전략적 파트너십을 발표하여 최초의 다자산 C10 재무 자산 배분을 실행합니다.
회사는 시가총액 가중치가 반영된 세계 상위 10개 암호자산의 3000만 달러짜리 바스켓(스테이블코인 제외)에 전념했습니다. BitGo는 OTC 실행, 깊은 유동성에 대한 접근성, 규제된 콜드 보관 및 준수 프로토콜을 제공하여 Qualigen의 재무 자산을 보호합니다.
이 움직임은 Qualigen의 다각화된 디지털 자산 재무 전략으로의 전환을 공식화하며, BitGo의 기관용 인프라를 활용해 재무 운영을 간소화합니다.
Qualigen Therapeutics (NASDAQ : QLGN) a annoncé un partenariat stratégique avec BitGo le 23 octobre 2025 afin d'exécuter sa première allocation de trésorerie multi-actifs C10.
L'entreprise a engagé un panier pondéré par capitalisation boursière de 30 millions de dollars parmi les dix principaux actifs crypto mondiaux (hors stablecoins). BitGo fournira une exécution OTC, un accès à une liquidité profonde et une garde à froid réglementée avec des protocoles de conformité pour protéger les actifs de trésorerie de Qualigen.
Cette démarche formalise le passage de Qualigen à une stratégie de trésorerie en actifs numériques diversifiée et exploite l'infrastructure institutionnelle de BitGo pour rationaliser les opérations de trésorerie.
Qualigen Therapeutics (NASDAQ: QLGN) kündigte eine strategische Partnerschaft mit BitGo am 23. Oktober 2025 an, um seine erste multi-Asset C10 Treasury Allocation umzusetzen.
Das Unternehmen verpflichtete einen marktkapitalisierungsgewichteteten Korb von 30 Millionen US-Dollar der weltweit führenden 10 Krypto-Assets (ohne Stablecoins). BitGo wird OTC-Ausführung, Zugang zu tiefer Liquidität und regulierte Cold Custody mit Compliance-Protokollen bereitstellen, um die Treasury-Vermögenswerte von Qualigen zu schützen.
Die Maßnahme formt den Wandel von Qualigen hin zu einer diversifizierten Digital-Asset-Treasury-Strategie und nutzt BitGos institutionelle Infrastruktur, um Treasury-Operationen zu optimieren.
Qualigen Therapeutics (ناسداك: QLGN) أعلنت عن شراكة استراتيجية مع BitGo في 23 أكتوبر 2025 لتنفيذ أول تخصيص للخزانة المتعدد الأصول C10.
التزمت الشركة بسلة مقيّمة حسب رأس المال السوقي قدرها 30 مليون دولار من أفضل 10 أصول تشفيرية في العالم (باستثناء العملات المستقرة). ستقدّم BitGo تنفيذ OTC، وإتاحة وصول إلى سيولة عميقة، وحفظًا باردًا تنظيميًا مع بروتوكولات امتثال لحماية أصول خزينة Qualigen.
هذه الخطوة تقرب Qualigen من اعتماد استراتيجية خزينة أصول رقمية متنوعة وتستفيد من البنية المؤسسية لـ BitGo لتسهيل عمليات الخزانة.
Qualigen Therapeutics (纳斯达克代码：QLGN) 于2025年10月23日宣布与 BitGo 达成战略伙伴关系，以执行其首个多资产的 C10 国库配置。
该公司承诺以市值加权的全球前10大加密资产组成一个价值 3000万美元的篮子（不包括稳定币）。BitGo 将提供场外交易执行、深度流动性接入，以及受监管的冷托管并配备合规协议，以保全 Qualigen 的国库资产。
此举正式将 Qualigen 推向多元化数字资产国库策略，并利用 BitGo 的机构化基础设施来简化国库运作。
- Committed $30 million to a market-cap-weighted C10 crypto basket
- Partnered with BitGo for regulated cold custody and compliance
- Access to BitGo OTC desk providing deep liquidity for multi-asset execution
- None.
Insights
Qualigen allocates
Qualigen partners with BitGo to execute a secured, multi-asset treasury allocation into a market‑cap weighted top‑10 crypto basket (C10), excluding stablecoins, using BitGo’s OTC desk and qualified cold custody.
Key dependencies include execution by BitGo’s OTC desk and custody safeguards; both are described as services provided by BitGo in the announcement. The concrete, monitorable item is the
Watch custodial confirmations, any subsequent filings or disclosures quantifying holdings, and timing of purchases in the near term.
Partnership signals treasury diversification into digital assets with custody and liquidity arrangements disclosed.
The company states it will use BitGo’s qualified custody and OTC liquidity to implement a market‑cap weighted C10 allocation; the release frames this as a strategic treasury approach rather than an operational change.
Risks and dependencies are operational and disclosure related: secure custody and compliant protocols are cited, and the only concrete figure given is
Expect further disclosure on holdings and valuation in subsequent reports or filings within standard reporting cycles; the announced figure provides a clear short‑term metric to track.
New York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or “Company”), a publicly-trading technology company majority owned by Faraday Future, today announced a strategic partnership with BitGo, the digital asset infrastructure company, to support its C10 treasury strategy, which accumulate and compound a market-cap-weighted basket of the world’s top 10 crypto assets (excluding stablecoins).
Through this partnership, Qualigen will leverage BitGo’s holistic treasury management offering1 that combines access to deep liquidity with secure qualified custody. BitGo’s OTC desk will enable Qualigen to efficiently invest across a diversified basket of 10 digital assets marking a significant milestone in Qualigen’s forward-looking treasury strategy.
Qualigen’s treasury assets will be safeguarded by BitGo in secure, regulated cold storage with compliance protocols that meet the highest security standards. With over a decade of digital asset expertise, BitGo streamlined treasury management solution eliminates the complexities typically associated with institutional digital asset adoption allowing Qualigen to focus on its long-term vision for sustainable growth and digital integration.
“Qualigen has always stood at the intersection of innovation and technology,” said Jerry Wang, Co-CEO at Qualigen. “Our partnership with BitGo allows us to further diversify our corporate treasury with digital assets, reflecting our commitment to both financial resilience and leadership in the evolving digital economy.”
“We are proud to partner with Qualigen, a company that is redefining the future of mobility,” said Mike Belshe, CEO at BitGo. “This
This partnership highlights the accelerating convergence between cutting-edge technology and digital finance, positioning Qualigen as one of the first global technology innovators to adopt a diversified digital asset treasury strategy.
About BitGo
BitGo is the digital asset infrastructure company, delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. Since our founding in 2013, BitGo has been focused on accelerating the transition of the financial system to a digital asset economy. With a global presence and multiple regulated entities, BitGo serves thousands of institutions, including many of the industry's top brands, exchanges, and platforms, and millions of investors.
Services provided by BitGo and its affiliated entities.
Media Contact
press@bitgo.com
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a biotechnology company headquartered in Carlsbad, California, focused on developing and commercializing innovative oncology and immunology therapeutics. The Company is actively pursuing crypto and web3 strategic initiatives that integrate advanced technologies and capital market innovation to accelerate global growth.
Investor & Media Contact
Investor Relations Department
Qualigen Therapeutics, Inc.
5857 Owens Avenue, Suite 300, Carlsbad, CA 92008
Tel: +1 (760) 452-8111
Email: info@qualigeninc.com
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. The Company’s forward-looking statements are based on current beliefs and expectations of its management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the timing of the offering. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions the Company makes that later turn out to be incorrect, or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, including the Company’s ability to file its Form 10-Q for the period ended September 30, 2024, or otherwise in the future, or otherwise maintain compliance with any other listing requirement of The Nasdaq Capital Market, the potential de-listing of the Company’s shares from The Nasdaq Capital Market due to its failure to comply with the Nasdaq’s continued listing requirement, or its alternatives, or otherwise in the future, and the other risks set forth in the Company’s filings with the Securities and Exchange Commission, including in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by the Company’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Investor Relations
ir@qlgntx.com.
FAQ
What did Qualigen (QLGN) announce on October 23, 2025 about its treasury?
How will BitGo support Qualigen's treasury strategy for QLGN?
What assets are included in Qualigen's C10 allocation announced by QLGN?
How large is Qualigen's digital-asset allocation and when was it announced?
Does the QLGN announcement mention custody or security for the crypto treasury?
